J&J buys Aragon’s prostate cancer arm


Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.


Related Content

Genentech to buy breast cancer specialist Seragon

2 July 2014 Business

news image

$1.7bn deal for hormone receptor-destroying drug pipeline

Business roundup

30 June 2011 Business

news image

Industry news, July 2011

Most Read

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

History of King Richard III written in his teeth

18 August 2014 Research

news image

Chemical analysis of isotope signatures in monarch's remains provide insight into his life

Most Commented

The energy to fight injustice

23 July 2014 Comments

news image

Giving the world carbon-free energy means putting nuclear energy back on the agenda, says James Hansen

Next Mars rover will make oxygen from CO2

4 August 2014 News and Analysis

news image

Mars 2020 will set Nasa’s space exploration on a self-sufficiency course